+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Psoriatic Arthritis Treatment Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5214713
  • Report
  • December 2020
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Celgene Corporation
  • Hoffmann La Roche Ltd.
  • Merck & Co
  • Pfizer
  • MORE
Psoriatic Arthritis Treatment Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global psoriatic arthritis treatment market.

This report focuses on psoriatic arthritis treatment market which is experiencing strong growth. The report gives a guide to the psoriatic arthritis treatment market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the psoriatic arthritis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Psoriatic Arthritis Treatment market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider psoriatic arthritis treatment market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The psoriatic arthritis treatment market section of the report gives context. It compares the psoriatic arthritis treatment market with other segments of the psoriatic arthritis treatment market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, psoriatic arthritis treatment indicators comparison.
Scope

Markets Covered:
1) By Drug Class: Nonsteroidal anti-inflammatory drugs (NSAIDs); Disease-modifying anti-rheumatic drugs (DMARDs); Biologics; Others
2) By Route of Administration: Oral; Parenteral; Topical
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned: Amgen; Johnson & Johnson; Bristol-Myers Squibb Company; Celgene Corporation; Novartis

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Celgene Corporation
  • Hoffmann La Roche Ltd.
  • Merck & Co
  • Pfizer
  • MORE
1. Executive Summary

2. Psoriatic Arthritis Treatment Market Characteristics

3. Psoriatic Arthritis Treatment Market Size and Growth
3.1. Global Psoriatic Arthritis Treatment Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Psoriatic Arthritis Treatment Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Psoriatic Arthritis Treatment Market Segmentation
4.1. Global Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Disease-modifying anti-rheumatic drugs (DMARDs)
  • Biologics
  • Others
4.2. Global Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Oral
  • Parenteral
  • Topical
4.3. Global Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
5. Psoriatic Arthritis Treatment Market Regional and Country Analysis
5.1. Global Psoriatic Arthritis Treatment Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Psoriatic Arthritis Treatment Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Psoriatic Arthritis Treatment Market
6.1. Asia-Pacific Psoriatic Arthritis Treatment Market Overview
6.2. Asia-Pacific Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Psoriatic Arthritis Treatment Market
7.1. China Psoriatic Arthritis Treatment Market Overview
7.2. China Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Psoriatic Arthritis Treatment Market
8.1. India Psoriatic Arthritis Treatment Market Overview
8.2. India Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Psoriatic Arthritis Treatment Market
9.1. Japan Psoriatic Arthritis Treatment Market Overview
9.2. Japan Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Psoriatic Arthritis Treatment Market
10.1. Australia Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Psoriatic Arthritis Treatment Market
11.1. Indonesia Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Psoriatic Arthritis Treatment Market
12.1. South Korea Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Psoriatic Arthritis Treatment Market
13.1. Western Europe Psoriatic Arthritis Treatment Market Overview
13.2. Western Europe Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Psoriatic Arthritis Treatment Market
14.1. UK Psoriatic Arthritis Treatment Market Overview
14.2. UK Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Psoriatic Arthritis Treatment Market
15.1. Germany Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Psoriatic Arthritis Treatment Market
16.4. France Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Psoriatic Arthritis Treatment Market
17.1. Eastern Europe Psoriatic Arthritis Treatment Market Overview
17.2. Eastern Europe Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Psoriatic Arthritis Treatment Market
18.1. Russia Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Psoriatic Arthritis Treatment Market
19.1. North America Psoriatic Arthritis Treatment Market Overview
19.2. North America Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Psoriatic Arthritis Treatment Market
20.1. USA Psoriatic Arthritis Treatment Market Overview
20.2. USA Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Psoriatic Arthritis Treatment Market
21.1. South America Psoriatic Arthritis Treatment Market Overview
21.2. South America Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Psoriatic Arthritis Treatment Market
22.1. Brazil Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Psoriatic Arthritis Treatment Market
23.1. Middle East Psoriatic Arthritis Treatment Market Overview
23.2. Middle East Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Psoriatic Arthritis Treatment Market
24.1. Africa Psoriatic Arthritis Treatment Market Overview
24.2. Africa Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Psoriatic Arthritis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Psoriatic Arthritis Treatment Market Competitive Landscape and Company Profiles
25.1. Psoriatic Arthritis Treatment Market Competitive Landscape
25.2. Psoriatic Arthritis Treatment Market Company Profiles
25.2.1. Amgen
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Johnson & Johnson
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Bristol-Myers Squibb Company
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Celgene Corporation
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Novartis
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers and Acquisitions In The Psoriatic Arthritis Treatment Market

27. Psoriatic Arthritis Treatment Market Trends and Strategies

28. Psoriatic Arthritis Treatment Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca
  • Celgene Corporation
  • Hoffmann La Roche Ltd.
  • Merck & Co
  • Pfizer
  • MORE
Major players in the psoriatic arthritis treatment market are AbbVie, Amgen, Johnson & Johnson, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly And Company, Pfizer, UCB Biosciences Inc, and Hoffmann La Roche Ltd.

The global psoriatic arthritis treatment market is expected to decline from $7.47 billion in 2019 to $7.32 billion in 2020 at a compound annual growth rate (CAGR) of -1.98%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $9.87 billion in 2023 at a CAGR of 10.45%.

The psoriatic arthritis treatment market consists of the sale of psoriatic arthritis drugs used for the treatment of psoriatic arthritis by entities producing drugs for psoriatic arthritis. Psoriasis arthritis is a chronic inflammatory joint disease that is associated with psoriasis, whose symptoms vary from person to person.

In 2019, Amgen Inc., an American biopharmaceutical company headquartered in Thousand Oaks, California, acquired Celgene’s Otezla for $13.4 billion. Otezla supports Amgen’s mission to bring innovative medicines to patients and expand its product portfolio. Amgen also gets worldwide rights with Otezla's acquisition. Otezla (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis and active psoriatic arthritis. Celgene Corporation is a US-based biopharmaceutical company, acquired by Bristol-Myers Squibb Company, which develops and markets drugs used in the treatment of cancer and anti-inflammatory diseases.

The psoriatic arthritis treatment market covered in this report is segmented by drug class into nonsteroidal anti-inflammatory drugs (NSAIDs); disease-modifying anti-rheumatic drugs (DMARDS); biologics; others. It is also segmented by route of administration into oral; parenteral; topical and by distribution channel into hospital pharmacies; retail pharmacies; online pharmacies.

The development of novel drugs such as Janus kinase (JAK) inhibitors for treating psoriatic arthritis is shaping the market. Janus kinase (JAK) inhibitors are orally administered small molecules emerging as a novel treatment for psoriatic arthritis patients. There are three JAK inhibitors approved for the treatment of autoimmune diseases – tofacitinib, baricitinib, and upadacitinib. Among them, Xeljanz (tofacitinib) and Xeljanz (tofacitinib) XR are the first Janus kinase (JAK) inhibitors that have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). They are used to treat adult patients with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). In June 2020, AbbVie, a leading US-based pharmaceutical company has announced that it has applied for the approval of upadacitinib (RINVOQ), a JAK inhibitor with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The rise in the prevalence of psoriasis & psoriatic arthritis disease boosted the growth of the psoriatic arthritis treatment market. Psoriasis (Pso) and psoriatic arthritis (PsA) are inflammatory disorders that can severely impair health and quality of life. Psoriasis is associated with inflammatory arthritis, known as psoriatic arthritis (PsA), with an incidence of 30% in psoriatic patients. According to the national psoriasis foundation, more than 8 million Americans have psoriasis. According to the National Psoriasis Foundation, in the USA, about 30% of people with psoriasis also develop psoriatic arthritis. Thus, an increase in the prevalence of psoriasis & psoriatic arthritis disease drives market growth.
Note: Product cover images may vary from those shown
4 of 5
  • AbbVie
  • Amgen
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Novartis
  • Eli Lilly And Company
  • Pfizer
  • UCB Biosciences Inc
  • Hoffmann La Roche Ltd.
  • Merck & Co
  • AstraZeneca
  • Sanofi
  • Otsuka Pharmaceutical
  • Sumitomo Dainippon Pharma Co
  • Bayer
  • Abbott Laboratories
  • Eisai Inc
  • Janssen Biotech
  • Bausch Health Companies
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll